Goldman Sachs’s VIVEVE MED INC VIVE Stock Holding History

Goldman Sachs’s Portfolio VIVE Stock Details VIVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-65,000	Closed	-$192K	–	6629
2021 Q2	$192K	Buy	65,000 +47,600	+274%	+$134K	﹤0.01%	5754
2021 Q1	$53K	Buy	+17,400	New	+$63.9K	﹤0.01%	5937
2019 Q4	–	Sell	-2,369	Closed	-$104K	–	5468
2019 Q3	$104K	Buy	+2,369	New	+$427K	﹤0.01%	4957
2018 Q4	–	Sell	-37	Closed	-$99K	–	5804
2018 Q3	$99K	Sell	37 -37	-50%	-$105K	﹤0.01%	5140
2018 Q2	$202K	Buy	74 +51	+222%	+$147K	﹤0.01%	4988
2018 Q1	$84K	Buy	23 +3	+15%	+$13K	﹤0.01%	5342
2017 Q4	$100K	Sell	20 -4	-17%	-$20.8K	﹤0.01%	5744
2017 Q3	$128K	Buy	+24	New	+$148K	﹤0.01%	5966
2017 Q2	–	Sell	-24	Closed	-$155K	–	7049
2017 Q1	$155K	Sell	24 -5	-17%	-$24.3K	﹤0.01%	5857
2016 Q4	$149K	Sell	29 -9	-24%	-$53.6K	﹤0.01%	5950
2016 Q3	$271K	Buy	+38	New	+$252K	﹤0.01%	5562

Other funds holding VIVE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Goldman Sachs's VIVE Position: Q3 2021 in Review

Goldman Sachs sold out of VIVEVE MED INC (VIVE) in Q3 2021, closing a stake of 65,000 shares — an estimated $192K sold.

Goldman Sachs first reported a position in VIVE in Q3 2016 and held it in 11 quarters. The position peaked at $271K in Q3 2016. 16 funds tracked by Wall St. Rank hold VIVE as of Q3 2021.

Goldman Sachs reported no remaining VIVEVE MED INC position as of Q3 2021 after selling out during the quarter.
Goldman Sachs sold 65,000 VIVEVE MED INC shares in Q3 2021, an estimated $192K.
Goldman Sachs first reported a position in VIVEVE MED INC in Q3 2016 and held it in 11 quarters.
Goldman Sachs's VIVEVE MED INC position peaked at $271K in Q3 2016.
16 funds tracked by Wall St. Rank held VIVEVE MED INC as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.